U.S. Pharma Stock News

NYSE:FOUR
NYSE:FOURDiversified Financial

Shift4 Payments (FOUR) Margin Squeeze And Q1 Loss Test High Growth Narratives

Shift4 Payments (FOUR) opened Q1 2026 with total revenue of US$1.1 billion and a small net loss of US$1 million, translating into basic EPS of about US$0.01 loss. Trailing 12 month revenue sat at US$4.5 billion and net income at US$62 million. Over recent quarters, revenue has moved from US$848.3 million in Q1 2025 to US$1.1 billion in Q1 2026 as quarterly EPS shifted from US$0.24 to a slight loss. This sets up a story where top line scale is meeting tighter margins. With earnings forecasts...
NYSE:SYY
NYSE:SYYConsumer Retailing

A Look At Sysco (SYY) Valuation After Q3 Sales Growth And Softer Net Income

Sysco (SYY) has just released its third quarter results, providing fresh numbers on how the foodservice distributor is performing. The update shows higher sales alongside lower net income compared with a year earlier. See our latest analysis for Sysco. Sysco’s share price has softened in the short term, with a 1 day share price return of 0.61% and a 90 day share price return of 15.77% decline, while the 1 year total shareholder return of 4.71% points to steadier longer term momentum as...
NYSE:JCI
NYSE:JCIBuilding

Is It Too Late To Consider Johnson Controls International (JCI) After Strong Multi Year Rally?

If you are wondering whether Johnson Controls International at around US$139 per share still offers value, the key question is how that price compares with what the business might be worth. The stock has been volatile recently, with a 4.6% decline over the last 7 days, a 4.6% gain over the past month, and returns of 13.9% year to date, 54.7% over 1 year, 137.8% over 3 years and 139.6% over 5 years. Recent headlines have focused on Johnson Controls International as investors reassess large...
NYSE:BAX
NYSE:BAXMedical Equipment

How Modest Sales Growth And A Surprise Loss At Baxter (BAX) Has Changed Its Investment Story

In late April 2026, Baxter International reported first-quarter sales of US$2,701 million versus US$2,625 million a year earlier, while swinging from a net income of US$126 million to a net loss of US$15 million, and reiterated its unaudited 2026 U.S. GAAP sales outlook for flat to 1% growth. At the same time, Baxter moved to refine its governance structure by seeking stockholder approval to resize its board within clearer limits and affirmed a quarterly dividend of US$0.01 per share,...
NasdaqGS:HIMX
NasdaqGS:HIMXSemiconductor

Is It Too Late To Reassess Himax Technologies (HIMX) After Its Surging Share Price?

If you are wondering whether Himax Technologies at US$16.03 is priced attractively or already baking in a lot of optimism, it helps to step back and look at what the recent data is actually saying about value. The stock has posted returns of 36.4% over 7 days, 83.6% over 30 days, 87.9% year to date, 120.2% over 1 year, 180.8% over 3 years, and 102.0% over 5 years, which can shift how the market views both its potential and its risks. These moves have kept Himax Technologies on the radar of...
NYSE:PLD
NYSE:PLDIndustrial REITs

Is It Too Late To Consider Prologis (PLD) After Its 40% One Year Rally?

If you are wondering whether Prologis at around US$142 a share still offers value, it helps to step back and look at what the recent share price and fundamentals are really telling you. Over the last year, Prologis has posted a 39.6% return, with gains of 10.3% year to date, 6.8% over the past month, and 0.2% over the last week, which can shift how the market is thinking about both reward potential and risk. Recent headlines around Prologis have largely focused on its role in logistics real...
NasdaqGS:EMBC
NasdaqGS:EMBCMedical Equipment

Embecta (EMBC) Is Down 60.7% After Dividend Cut And Buyback Shift - What's Changed

In early May 2026, Embecta Corp. reported a year-over-year drop in quarterly sales to US$221.8 million and swung from a net income of US$23.5 million to a net loss of US$4.1 million, while also slashing its quarterly dividend to US$0.01 per share and authorizing a three-year, US$100 million share repurchase program. The combination of weaker Q2 results, lowered full-year guidance, a sharply reduced dividend, and the planned Owen Mumford acquisition highlights how Embecta is reshaping its...
NasdaqGS:CRTO
NasdaqGS:CRTOMedia

Criteo (CRTO) Is Down 13.1% After Weak Q1 2026 Results And Redomiciliation Plan - What's Changed

Criteo S.A. has reported past first-quarter 2026 results showing sales of US$424.64 million versus US$451.43 million a year earlier, with net income falling to US$7.82 million from US$37.93 million and diluted EPS from continuing operations declining to US$0.15 from US$0.66. Alongside weaker Retail Media performance and lower profitability, Criteo is proceeding with a legal redomiciliation to Luxembourg aimed at easing buyback constraints and improving access to U.S. capital markets. We’ll...
NasdaqGS:DASH
NasdaqGS:DASHHospitality

DoorDash (DASH) Q1 Net Margin At 6.3% Tests Bullish Profitability Narrative

Q1 2026 results set the scene DoorDash (DASH) opened 2026 with Q1 revenue of US$4.0 billion and basic EPS of US$0.42, setting a clear benchmark for how the business is currently converting its scale into per share profitability. The company has seen quarterly revenue move from US$2.9 billion in Q4 2024 to US$3.0 billion in Q1 2025 and then to US$4.0 billion in Q1 2026, while basic EPS over the same period went from US$0.34 to US$0.46 and then US$0.42, giving investors a clean view of how...
NYSE:LNG
NYSE:LNGOil and Gas

Cheniere Energy Q1 Loss Of US$3.5b Tests Bullish Contract Stability Narrative

Cheniere Energy (LNG) opened Q1 2026 with revenue of US$5.9b and a basic EPS loss of US$16.64, compared with Q1 2025 revenue of US$5.4b and basic EPS of US$1.57. Trailing twelve month EPS sits at US$6.75 on revenue of US$19.9b. Over the last few quarters, revenue has moved from US$4.5b in Q4 2024 to US$5.0b in Q4 2025 and EPS has ranged from US$4.35 to US$10.72 before this latest quarterly loss. This leaves investors weighing a fuller year of positive EPS against a tough quarter for margins...
NYSE:FLS
NYSE:FLSMachinery

Will Flowserve’s (FLS) Debt-Funded Trillium Deal And Lower Guidance Change Its Margin Progress Narrative?

In early May 2026, Flowserve Corporation completed a US$500 million offering of 5.70% senior unsecured notes due 2036, primarily to fund its planned acquisition of Trillium Flow Technologies’ Valves Division and for general corporate purposes, alongside reporting first-quarter sales of US$1,068.27 million and net income of US$81.68 million. At the same time, the company lowered its 2026 total sales growth guidance to a range of 3% to 6%, signaling a more cautious outlook even as it pursues...
NYSE:ARES
NYSE:ARESCapital Markets

Will Ares’ Record Q1 Fundraising, Higher Dividend and New COO Change Ares Management’s (ARES) Narrative?

Ares Management Corporation has already reported first-quarter 2026 results, with revenue rising to US$1,396.44 million and net income to US$142.59 million, while also lifting its quarterly common dividend to US$1.35 per share and maintaining preferred dividends. The appointment of Peter Ogilvie as Chief Operating Officer and Head of Strategy, alongside record fundraising and expanding assets under management, highlights Ares’ focus on scaling its global alternatives platform and reinforcing...
NasdaqGS:ENTG
NasdaqGS:ENTGSemiconductor

How Investors Are Reacting To Entegris (ENTG) Strong Q1 Results, Upbeat Guidance, Expanded Credit Line, New CFO

Entegris, Inc. recently reported first-quarter 2026 results showing higher sales and net income year on year, issued stronger earnings guidance for the next two quarters, amended its revolving credit facility to US$750.00 million through 2031, and appointed industry veteran Sukhi Nagesh as CFO effective May 18, 2026. Together, these updates highlight Entegris’ focus on reinforcing its balance sheet, tightening operations, and deepening semiconductor-sector expertise in its finance leadership...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Clover Health (CLOV) Quarterly Profit Challenges Longstanding Bearish Loss Narratives

Clover Health Investments (CLOV) opened Q1 2026 with revenue of US$749.2 million and basic EPS of US$0.05, alongside net income excluding extra items of US$27.3 million, giving investors a clean read on the core business. Over the last five reported quarters, revenue has moved from US$336.9 million in Q4 2024 to US$749.2 million in Q1 2026, while quarterly basic EPS has shifted from a loss of US$0.04 to a profit of US$0.05. This sets up this update as a key check on whether those improving...